# A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

> **NCT05510245** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Type 2 Diabetes
- Renal Impairment

## Interventions

- **DRUG:** PF-07081532

## Key facts

- **NCT ID:** NCT05510245
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-29
- **Primary completion:** 2023-07-20
- **Final completion:** 2023-07-20
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05510245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05510245, "A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05510245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*